S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:AVRO - Avrobio Stock Price, Forecast & News

$16.53
+1.66 (+11.16 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$14.08
Now: $16.53
$16.59
50-Day Range
$10.08
MA: $19.39
$27.21
52-Week Range
$9.76
Now: $16.53
$29.32
Volume298,441 shs
Average Volume343,729 shs
Market Capitalization$595.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
Avrobio logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
CUSIPN/A
CIKN/A
Phone617-914-8420

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.87 per share

Profitability

Net Income$-72,960,000.00

Miscellaneous

Employees49
Market Cap$595.58 million
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.


Avrobio (NASDAQ:AVRO) Frequently Asked Questions

How has Avrobio's stock been impacted by COVID-19 (Coronavirus)?

Avrobio's stock was trading at $18.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 8.3% and is now trading at $16.53. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avrobio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avrobio.

When is Avrobio's next earnings date?

Avrobio is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Avrobio.

How were Avrobio's earnings last quarter?

Avrobio Inc (NASDAQ:AVRO) released its quarterly earnings results on Monday, March, 16th. The company reported ($0.72) EPS for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.13. View Avrobio's earnings history.

What price target have analysts set for AVRO?

7 analysts have issued 12 month price objectives for Avrobio's shares. Their forecasts range from $24.42 to $43.00. On average, they anticipate Avrobio's stock price to reach $36.24 in the next twelve months. This suggests a possible upside of 119.2% from the stock's current price. View analysts' price targets for Avrobio.

Has Avrobio been receiving favorable news coverage?

Headlines about AVRO stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avrobio earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAvrobio.

Are investors shorting Avrobio?

Avrobio saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,551,600 shares, an increase of 6.3% from the February 27th total of 1,460,000 shares. Based on an average daily trading volume, of 241,700 shares, the days-to-cover ratio is presently 6.4 days. Currently, 11.7% of the shares of the stock are sold short. View Avrobio's Current Options Chain.

Who are some of Avrobio's key competitors?

What other stocks do shareholders of Avrobio own?

Who are Avrobio's key executives?

Avrobio's management team includes the following people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)
  • Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Erik Ostrowski, CFO & Treasurer (Age 46)
  • Dr. Kim Warren, Head of Operations

When did Avrobio IPO?

(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is Avrobio's stock symbol?

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Who are Avrobio's major shareholders?

Avrobio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (3.16%), Emerald Advisers LLC (2.07%), State Street Corp (2.03%), Victory Capital Management Inc. (1.41%), Victory Capital Management Inc. (1.32%) and Geode Capital Management LLC (0.93%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View institutional ownership trends for Avrobio.

Which institutional investors are selling Avrobio stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., UBS Group AG, AlpInvest Partners B.V., Victory Capital Management Inc., Nuveen Asset Management LLC, Rafferty Asset Management LLC, Bank of America Corp DE, and Goldman Sachs Group Inc.. Company insiders that have sold Avrobio company stock in the last year include Christopher Paige, and Geoffrey Mackay. View insider buying and selling activity for Avrobio.

Which institutional investors are buying Avrobio stock?

AVRO stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Tang Capital Management LLC, FMR LLC, Parkman Healthcare Partners LLC, California Public Employees Retirement System, Spark Investment Management LLC, Nisa Investment Advisors LLC, and UBS Asset Management Americas Inc.. View insider buying and selling activity for Avrobio.

How do I buy shares of Avrobio?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avrobio's stock price today?

One share of AVRO stock can currently be purchased for approximately $16.53.

How big of a company is Avrobio?

Avrobio has a market capitalization of $595.58 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe. View additional information about Avrobio.

What is Avrobio's official website?

The official website for Avrobio is http://www.avrobio.com/.

How can I contact Avrobio?

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]


MarketBeat Community Rating for Avrobio (NASDAQ AVRO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote "Outperform" if you believe AVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Fibonacci Channel

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel